Proteinuria Market

 Market Overview:

The 7 major proteinuria markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 6.14% during 2024-2034.

The proteinuria market has been comprehensively analyzed in IMARC's new report titled "Proteinuria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Proteinuria refers to a medical condition characterized by the presence of excess protein in the urine. It does not cause noticeable symptoms on its own and is often detected through urine tests during routine check-ups or when investigating other health concerns. However, in some patients, proteinuria may be accompanied by various signs and indications, such as foamy or frothy urine, swelling in the hands, feet, or face (edema), unexplained weight gain, fatigue, frequent urination, etc. Diagnosing the ailment involves a series of steps to determine the presence, severity, and underlying cause of excess protein in the urine. Initially, a healthcare provider may perform a urine dipstick test, which offers a qualitative assessment of protein levels. If proteinuria is detected, further diagnostic tests, such as a urine protein-to-creatinine ratio (PCR) or albumin-to-creatinine ratio (ACR), are conducted to get a more accurate measure of protein excretion. In some cases, a 24-hour urine collection may be performed to quantify the total amount of protein excreted. Additionally, numerous imaging studies, including ultrasound and CT scans, may be conducted to assess kidney structure and function. If necessary, a renal biopsy is also performed to evaluate kidney tissue and identify the underlying cause of proteinuria.

The escalating cases of kidney diseases, such as glomerulonephritis, diabetic nephropathy, nephrotic syndrome, etc., which affect the filtering units of the kidneys, thereby leading to abnormal protein leakage into the urine, are primarily driving the proteinuria market. Furthermore, the rising incidence of several associated risk factors, including urinary tract infections (UTIs), preeclampsia, genetic predisposition, congestive heart failure, hypertension, etc., is also bolstering the market growth. In addition to this, the widespread adoption of renoprotective medications, such as mineralocorticoid receptor antagonists and endothelin receptor antagonists, for slowing the progression of kidney damage in patients is creating a positive outlook for the market. Moreover, several key players are making extensive investments in research activities to develop novel immunomodulatory drugs that target specific inflammatory pathways and aid to reduce protein leakage. This, in turn, is also acting as another significant growth-inducing factor. Additionally, the emerging popularity of the fractional excretion of proteins (FEP) test, since it helps to differentiate between various types of proteinuria and provides insights into the site as well as the mechanism of protein leakage, is expected to drive the proteinuria market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the proteinuria market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for proteinuria and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the proteinuria market in any manner.

Recent Developments:

• In August 2024, Novartis stated that the United States Food and Drug Administration (FDA) had granted accelerated clearance for Fabhalta (iptacopan), a first-in-class complement inhibitor for the decrease of proteinuria in people with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression.

Key Highlights:

• The prevalence of proteinuria in the general population ranges from 8% to 33%
• The incidence of chronic proteinuria in affected individuals has been estimated to be 15.3 per 1000 person-years.
• Persistent proteinuria is twice as common in men as in women.
• Proteinuria is more common in metropolitan and small-medium sized cities than in rural areas.
• Proteinuria is more common after the age of 40.

Drugs:

ALXN1720 is a bispecific antibody being developed by Alexion Pharmaceuticals to treat proteinuria. It is injected either intravenously or subcutaneously. ALXN1720 operates by focusing on complement component 5 (C5) and preventing its cleavage into C5a and C5b. It also binds to albumin, prolonging its half-life.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the proteinuria market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the proteinuria market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current proteinuria marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the proteinuria market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the proteinuria market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the proteinuria market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of proteinuria across the seven major markets?
• What is the number of prevalent cases (2018-2034) of proteinuria by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of proteinuria by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with proteinuria across the seven major markets?
• What is the size of the proteinuria patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of proteinuria?
• What will be the growth rate of patients across the seven major markets?
   

Proteinuria: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for proteinuria drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the proteinuria market?
• What are the key regulatory events related to the proteinuria market?
• What is the structure of clinical trial landscape by status related to the proteinuria market?
• What is the structure of clinical trial landscape by phase related to the proteinuria market?
• What is the structure of clinical trial landscape by route of administration related to the proteinuria market?